{
  "abstract": "Lung cancer harboring epidermal growth factor receptor (EGFR) mutations exhibits marked heterogeneity in clinical responses to EGFR tyrosine kinase inhibitors (EGFR-TKIs), indicating that co-occurring genetic alterations critically influence therapeutic outcomes. However, the underlying mechanisms remain incompletely understood. Here, we modeled frequent EGFR co-alterations using CRISPR-mediated gene knockout and Tet-On-based gene overexpression in two EGFR-mutant cell lines. Functional screening across cell lines and patient-derived organoids revealed that concurrent loss of retinoblastoma 1 (RB1) significantly reduced sensitivity to EGFR-TKIs. Integrated transcriptomic and metabolomic analyses further demonstrated that RB1 deficiency induced extensive metabolic reprogramming, leading to decreased intracellular crotonyl-CoA levels and reduced histone crotonylation. Among multiple crotonylation sites, histone H3 lysine 23 crotonylation (H3K23cr) emerged as a critical determinant of EGFR-TKI responsiveness. Mechanistically, decreased H3K23cr was associated with transcriptional repression of PEBP1 and reduced expression of the PEBP1-encoded Raf kinase inhibitor protein (RKIP), thereby sustaining RAF/MEK/ERK pathway activation and attenuating EGFR-TKI efficacy. Importantly, pharmacological restoration of histone crotonylation or inhibition of MAPK signaling effectively resensitized EGFR/RB1 co-mutant models to EGFR-TKIs. Taken together, our findings identify a metabolic-epigenetic mechanism linking RB1 loss to reduced histone crotonylation and EGFR-TKI resistance, highlighting therapeutically actionable vulnerabilities in EGFR/RB1 co-mutant lung cancer.",
  "abstract_shown": true,
  "affiliations": [
    "Benxi Institute of Pharmaceutical Research, Shenyang Pharmaceutical University, Shenyang 110016, China",
    "Department of Thoracic Surgery, Chest Hospital of Shenyang Pharmaceutical University, Shenyang 110044, China",
    "Department of Thoracic Surgery, Shengjing Hospital of China Medical University, Shenyang 110004, China",
    "Department of Pharmacy, Shengjing Hospital of China Medical University, Shenyang 110004, China"
  ],
  "article_type": "research article",
  "arxiv": null,
  "author_total": 11,
  "authors": [
    {
      "affs": [
        0
      ],
      "name": "Sihong Chen"
    },
    {
      "affs": [
        0
      ],
      "name": "Xiaoyuan Wang"
    },
    {
      "affs": [
        0
      ],
      "name": "Qihao Xuan"
    },
    {
      "affs": [
        1
      ],
      "name": "Chang Liu"
    },
    {
      "affs": [
        0
      ],
      "name": "Youwei Su"
    },
    {
      "affs": [
        2
      ],
      "name": "Zongang Liu"
    },
    {
      "affs": [
        0
      ],
      "name": "Lina Jia"
    },
    {
      "affs": [
        1
      ],
      "name": "Yi Ren"
    },
    {
      "affs": [
        0
      ],
      "name": "Wei Cui"
    },
    {
      "affs": [
        3
      ],
      "name": "Xinyu Fan"
    },
    {
      "affs": [
        0
      ],
      "name": "Lihui Wang"
    }
  ],
  "bibtex": "https://research.draconitic.com/paper/e2bxsncprezjn.bib",
  "cited_by": 0,
  "doi": "10.1016/j.apsb.2026.08.007",
  "fulltext_url": "https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13730233/?tool=EBI",
  "id": "e2bxsncprezjn",
  "issns": [
    "2211-3835",
    "2211-3843"
  ],
  "landing_url": "https://europepmc.org/article/PMC/PMC13730233",
  "language": "eng",
  "licence": "CC-BY-NC-ND",
  "licence_label": "CC BY-NC-ND",
  "licence_source": "article",
  "licence_url": "https://creativecommons.org/licenses/by-nc-nd/4.0/",
  "metadata_licence": null,
  "native_subjects": [
    [
      "heading",
      "Original Article"
    ],
    [
      "openalex",
      "2740|Lung Cancer Treatments and Mutations"
    ]
  ],
  "openalex": "W7201957295",
  "pdf_url": "https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13730233/pdf/?tool=EBI",
  "pmcid": "PMC13730233",
  "pmid": "42979327",
  "published": "2026-08-08",
  "publisher": "Elsevier",
  "ris": "https://research.draconitic.com/paper/e2bxsncprezjn.ris",
  "sources": [
    {
      "first_seen": "2026-11-04T15:20:47Z",
      "native_id": "PMC:PMC13730233",
      "source": "europepmc",
      "url": "https://europepmc.org/article/PMC/PMC13730233"
    },
    {
      "first_seen": "2026-11-07T12:22:50Z",
      "native_id": "PMC13730233",
      "source": "pmc",
      "url": "https://doi.org/10.1016/j.apsb.2026.08.007"
    }
  ],
  "subjects": [
    {
      "field": "medicine",
      "origin": "openalex:2740|Lung Cancer Treatments and Mutations",
      "subfield": "general"
    }
  ],
  "title": "Concurrent loss of RB1 facilitates EGFR-TKI resistance in EGFR-mutant lung cancer by modulating histone crotonylation",
  "title_text": "Concurrent loss of RB1 facilitates EGFR-TKI resistance in EGFR-mutant lung cancer by modulating histone crotonylation",
  "type": "peer-reviewed",
  "updated_at": "2026-11-07T12:22:50Z",
  "url": "https://research.draconitic.com/paper/e2bxsncprezjn",
  "venue": "Acta pharmaceutica Sinica. B",
  "versions": []
}